研究单位：[1]Affiliated Hospital of Hebei university,BaoDing,Hebei,China
研究目的：
The purpose of this study is to assess the efficacy and safety of patients who receive apatinib plus docetaxel and zoledronic versus docetaxel and zoledronic alone as second line treatment for advanced non-squamous non-small cell lung cancer with bone metastases.
